Mirtazapine in pregnancy and lactation: data from a case series.

Depression is a common disorder in pregnancy and associated with adverse effects for both mother and neonate. Pharmacological treatment and prevention options include mirtazapine. In a series of 56 cases, we investigated neonatal outcome after intrauterine exposure to mirtazapine and exposure through lactation in the first days postpartum.

Risk factors for poor neonatal adaptation after exposure to antidepressants in utero.

Aim: Infants exposed to antidepressants in utero are at risk of developing poor neonatal adaptation (PNA). This study identified risk factors for PNA.

Methods: In this cohort study, data on mothers and infants admitted to the maternity ward of a general hospital between 2007 and 2012 were analysed.

Adapted Finnegan scoring list for observation of anti-depressant exposed infants.

Objective: The Finnegan scoring list (FSL) is widely used to screen for poor neonatal adaptation in infants exposed to anti-depressants in utero. However, the large number of FSL-items and differential weighing of each item is time consuming. The aim of this study was to shorten and simplify the FSL yet preserving its clinimetric properties.

[Withdrawal in newborns after exposure to psychotropic medications during pregnancy].

The use of psychotropic medications during pregnancy causes withdrawal symptoms in 20-30% of the newborns. The literature on withdrawal symptoms is not unanimous concerning their recognition and treatment. A search of PubMed and Embase revealed 198 articles in which potential withdrawal symptoms in newborns were described following exposure to psychotropic medications during pregnancy.

[Intrauterine exposure to SSRIs: no reason for routine hypoglycaemia screening].

Objective: To investigate whether neonates who have been exposed to selective serotonin reuptake inhibitors (SSRIs) in utero have a higher risk of hypoglycaemia than unexposed neonates.

Design: Systematic review of cohort studies.

Methods: We searched in PubMed and Embase for available cohort studies in which neonates exposed to SSRIs in utero were compared to non-exposed neonates, with hypoglycaemia as an outcome parameter.